Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

Фаза 3 Завершено NCT03702582

Кратко

This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.

Postoperative Length of Stay

Up to 6 months following the cardiac operation · days

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
• Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
• Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.
• Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintai — Ottawa Heart Institute Research Corporation

Все исследования